Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE
BVF PARTNERS L P/IL reported a 7.20% stake in Monte Rosa Therapeutics, Inc. (Schedule 13G)
Event Jan 24, 2025 · Filed Jan 31, 2025
BVF PARTNERS L P/IL reported a 7.20% stake in Monte Rosa Therapeutics, Inc., 4,393,210 shares, as a passive investor on Jan 24, 2025. Filed Jan 31, 2025 (Schedule 13G).
- Stake
- 7.20%
- Shares
- 4,393,210
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 10 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 3.70% | 2,257,204 |
| BVF I GP LLC | 3.70% | 2,257,204 |
| BIOTECHNOLOGY VALUE FUND II LP | 3.00% | 1,823,443 |
| BVF II GP LLC | 3.00% | 1,823,443 |
| Biotechnology Value Trading Fund OS LP | 0.40% | 228,202 |
| BVF Partners OS Ltd. | 0.40% | 228,202 |
| BVF GP HOLDINGS LLC | 6.60% | 4,080,647 |
| BVF PARTNERS L P/IL | 7.20% | 4,393,210 |
| BVF INC/IL | 7.20% | 4,393,210 |
| LAMPERT MARK N | 7.20% | 4,393,210 |
Source
Related
- Monte Rosa Therapeutics, Inc.
- Bvf Partners L P
- Monte Rosa Therapeutics, Inc. shareholders
- Schedule 13G/A · Bvf Partners L P · May 15, 2026
- Schedule 13G/A · Bvf Partners L P · Feb 17, 2026
- Schedule 13G/A · Bvf Partners L P · May 15, 2025
- Form 4 · Bowen Matthew · Oct 6, 2026
- Schedule 13G/A · Montanova Capital, LLC · Aug 14, 2026
- Schedule 13G · Vestal Point Capital, LP · Aug 14, 2026
- Form 4 · Warmuth Markus · Jul 17, 2026
- Form 4 · Champoux Jennifer · Jul 16, 2026